Innohep

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injectable solution for subcutaneous use. It treats and prevents venous thromboembolic disorders such as deep vein thrombosis and pulmonary embolism in surgical, medically ill, and acute settings.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, is used in the management of venous thromboembolic disease.

Prevention of deep vein thrombosis (DVT) in surgical patients: reduces clot formation after orthopedic or general surgery. Treatment of acute deep vein thrombosis: facilitates clot resolution and prevents extension. Prevention and treatment of pulmonary embolism: lowers risk of embolic events in at‑risk patients. Prophylaxis of thromboembolic events in medically ill patients: decreases incidence of DVT and PE during hospitalization.

Innohep may be associated with bleeding‑related and immune‑mediated reactions.

Common Side Effects: - Injection site erythema or pain - Minor bruising or hematoma at the injection site - Nausea - Transient elevation of liver enzymes - Mild headache

Serious or Rare Side Effects: - Major hemorrhage (e.g., gastrointestinal, intracranial) - Heparin‑induced thrombocytopenia (HIT) - Severe allergic reactions including anaphylaxis - Spinal or epidural hematoma after neuraxial procedures

Before initiating Innohep, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. Elderly patients: increased bleeding risk warrants careful observation. Concomitant antiplatelet therapy: heightened risk of bleeding when combined with aspirin or clopidogrel. History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence. Surgery or invasive procedures: discontinue Innohep prior to the procedure as advised by the surgeon. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep can interact with other medicines that affect haemostasis or platelet function.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increases risk of severe bleeding. - Systemic thrombolytic agents: additive anticoagulant effect may lead to uncontrolled hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may augment minor bleeding. - Antiplatelet agents (aspirin, clopidogrel): elevate overall bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs): can potentiate bleeding risk, especially gastrointestinal.